

## **ASX Announcement Results of Share Purchase Plan & Private Placement**

Melbourne, 15 February, 2013 – Consegna Group Limited ('Consegna' or 'Company') is pleased to announce that the Company has successfully closed its Share Purchase Plan ('SPP') announced on 18 December 2012. Consegna has received SPP applications for 113,625,000 new fully paid ordinary shares in the Company ('New Shares') at \$0.004 per New Share raising \$454,500. No applications under the SPP were scaled back.

In addition, the Company has further strengthened its balance sheet with a private placement of approximately 44,500,000 New Shares, also conducted at \$0.004 per New Share, raising approximately \$178,000. Shares issued under the private placement will be issued without prior shareholder approval and in accordance with ASX Listing Rule 7.1.

The SPP and private placement supplement the Company's recent private placement announced on 17 December 2012, also conducted at \$0.004 per share, which raised \$460,000.

Funds raised from the SPP and private placement will be used for working capital purposes and to drive the continued commercialization of the Company's BreatheAssist product suite.

Consegna Group's Chairman, Martin Rogers stated: "We are pleased by the solid SPP support from our shareholders in this time. Shareholder response and support has been very positive to our new executive director Michael Johnson. The Company will now focus on executing the next stages of the turnaround strategy over the next 3 months and looks forward to updating shareholders on how precisely the BreatheAssist assets will undergo commercialization and thus unlock value for all investors."

The remaining dates for the SPP are as follows:

<b>Event</b>	<b>Date</b>
Allotment and Issue of Shares under the SPP	By 18 February 2013
Application to ASX for quotation of Shares issued under SPP	By 18 February 2013

ENDS

### **About Consegna Group Limited**

Consegna Group Limited's purpose is to identify, acquire and commercialise late stage therapeutic delivery technologies. The Company targets high value markets and indications using an acquisition strategy driven by strategic value creation, patent protection and realisation criteria. The Company employs a low fixed overhead model with a panel of successful best in field regulatory, intellectual property and scientific advisors.



**CONSEGNA**  
DELIVERING INNOVATION

SUITE 1,  
1233 HIGH STREET,  
ARMADALE, VIC 3143

TEL. 03 9417 5001  
FAX. 03 8080 0796  
INFO@CONSEGNA.COM

ACN. 107 903 159